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Abstract: A major problem with anti-cancer drug treatment is the development of acquired 
multidrug resistance (MDR) of the tumor cells. Verotoxin-1 (VT-1) exerts its cytotoxicity 
by targeting the globotriaosylceramide membrane receptor (Gb3), a glycolipid associated 
with multidrug resistance. Gb3 is overexpressed in many human tumors and tumor cell 
lines with inherent or acquired MDR. Gb3 is co-expressed and interplays with the 
membrane efflux transporter P-gp encoded by the MDR1 gene. P-gp could act as a lipid 
flippase and stimulate Gb3 induction when tumor cells are exposed to cancer 
chemotherapy. Recent work has shown that apoptosis and inherent or acquired multidrug 
resistance in Gb3-expressing tumors could be affected by VT-1 holotoxin, a sub-toxic 
concentration of the holotoxin concomitant with chemotherapy or its Gb3-binding   
B-subunit coupled to cytotoxic or immunomodulatory drug, as well as chemical 
manipulation of Gb3 expression. The interplay between Gb3 and P-gp thus gives a   
possible physiological approach to augment the chemotherapeutic effect in multidrug   
resistant tumors.  
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1. Shiga Toxins 
The Shiga toxin family, a group of related exotoxins, includes Shiga toxin from Shigella dysenteriae 
and Shiga toxins such as verotoxin-1 (VT-1, Shiga-like toxin-1) produced by pathogenic strains of 
Escherichia coli [1–3]. 
VT-1 consists of one A and five B subunits. The B subunit binds to the neutral glycosphingolipid 
cell surface receptor globotriaosylceramide (Gb3) [4,5] and is endocytosed. The toxin then follows the 
retrograde pathway to the endoplasmic reticulum where the A-subunit is translocated to the cytosol 
and inhibits protein synthesis [6–12]. 
VT-1 also induces apoptosis through sequential activation of caspases, leading to nuclear changes, 
such as chromatin condensation and DNA fragmentation. VT-1-induced apoptosis in monocytic THP1 
cells requires retrograde transport through the Golgi apparatus to the ER and the activation of   
caspase-3, the executioner caspase [13]. Similar apoptotic signaling pathways are triggered by Shiga 
toxins in different cell lines.  
VT-1 induces a prominent ribotoxic stress signaling response leading to disrupted ribosomal RNA 
(rRNA) functions, protein synthesis inhibition and altered mitogen-activated protein kinase (MAPK) 
pathway signaling [14]. We found that MKK3/6 and JNK was phosphorylated after cisplatin treatment 
in the cisplatin-sensitive malignant pleural mesothelioma (MPM) cells, but not in the corresponding 
sub-lines with acquired-cisplatin resistance. VT-1 induced phosphorylation of MKK3/6, which was 
enhanced when VT-1 was combined with cisplatin [15]. MKK3/6 is known to activate P38 [16,17]. 
P38, as well as JNK, has been shown to promote apoptosis in response to cellular stress [18]. 
Treatment of cells with chemical inhibitors or siRNA targeting P38 was recently shown to specifically 
inhibit VT-1 transport to the Golgi apparatus complex and reduce VT-1 toxicity [19], and VT-1 
prolonged JNK and P38 MAPK activation of macrophage-like cells [20]. We have previously 
demonstrated JNK phosphorylation in response to VT-1 treatment also in glioma and breast cancer cell 
lines [21,22]. 
Apoptosis induced by VT-1 was associated with enhanced expression of the pro-apoptotic protein 
Bax [23] and overexpression of Bcl-2 protects cells against VT-1-induced cell death [24]. Shiga toxins 
also inhibit the expression of the anti-apoptotic Bcl-2 family member Mcl-1 [25]. Interestingly, 
acquisition of cisplatin resistance in MPM cells decreased cisplatin activation of the proapoptotic 
proteins of the Bcl-2 family of proteins [26] and increased the expression of apoptosis inhibitor 
proteins [27]. 
2. Glycosphingolipids and Globotriasosylceramide (Gb3) 
Glycosphingolipids (GSLs) are components of all vertebrate cells and play a fundamental role 
during development and cell differentiation [28]. GSLs are involved in cellular growth [29], signal 
transduction [30] and cell-cell interaction [31]. GSL profiling indicates that neutral globo series GSLs 
(including Gb3) have important roles in mediating MDR1 transactivation and expression [32]. Deletion 
of Gb3 synthase needed for Gb3 synthesis renders mice completely resistant to VT-1 and VT-2 [33] 
and GSLs are the only functional VT-1 receptors [34]. 
GSLs in cells are clustered and assembled with specific membrane proteins and signal transducers 
to form GSL-enriched microdomains or lipid rafts [35–37]. Rafts are rich in GSLs, cholesterol,   Toxins 2010, 2  
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lipid-modified- and transmembrane proteins [38]. The length of the fatty acyl chain of Gb3 influences 
its receptor function, intracellular sorting and retro-translocation of VT-1 to the cytosol [39,40]. 
Binding of VT-1 B-subunit with clustered raft-localized Gb3 receptors [41] is a requirement for the 
retrograde transport [42] and for a cytotoxic effect in the ER [43]. For cells with Gb3 present in the 
non-raft plasma membrane fraction, the toxin receptor complex is internalized and trafficked to 
lysosomes where the toxin is degraded, leading to VT-1 resistant cells. [44]. Furthermore, VT-1 B 
subunit binding to Gb3 induces lipid reorganization of the cell membrane leading to enhancement of 
VT-1 uptake into the cell [45]. 
Gb3 membrane organization also plays a central role in determining in vivo sensitivity to   
verotoxin-induced glomerular pathology of hemolytic uremia syndrome (HUS). Gb3 is distributed 
throughout the human nephron but only the Gb3 of the glomeruli is localized to lipid rafts making 
glomeruli sensitive to the cytopathology of systemic VT-1. The membrane organization of the 
glycosphingolipid receptor is the main discriminator for pathology in vivo [34,46]. 
The expression and metabolism of cell surface glycolipids is changed during oncogenic 
transformation and altered glycosylation patterns affect tumor invasion and metastasis [37]. Gb3 is 
expressed in several human malignancies including breast cancer [22] and testicular carcinoma [47]. 
Gb3 expression has been detected in lymphoma [48] and in various solid tumors [49]. Gb3 expression 
in colorectal cancer correlates with invasiveness and metastatic potential [50]. Elevated levels of Gb3 
have also been seen in drug-resistant cancers and cell lines and a functional interplay between 
membrane Gb3 and MDR1 has been suggested [51,52]. These findings suggest that the Gb3-binding 
specificity of VT-1 could be used to target tumors in the receptive cancer cells. 
3. Multidrug Resistance to Cancer Chemotherapy 
Poor response to cancer chemotherapy is usually due to drug resistance [53,54]. In breast cancer 
alone, nearly 50% of patients demonstrate primary and/or secondary resistance to doxorubicin [55].  
Tumor overexpression of the membrane efflux transporter P-glycoprotein (P-gp) is a common 
alteration in drug resistance [53,54,56]. P-gp, encoded by the MDR1 gene [57], was the first ABC 
protein demonstrated to confer resistance to cancer chemotherapeutics [58,59]. Other transporter 
proteins such as multidrug resistance protein (MRP1) and breast cancer resistance protein (BCRP) 
have also been described. P-gp plays roles in the absorption, distribution and excretion of compounds 
in normal tissues. Overexpression of MDR1 in tumors results in active efflux of several types of 
anticancer agents. P-gp is expressed by many types of primary solid tumors such as breast, colon, 
renal, and ovarian cancers, as well as hematological malignancies such as acute myeloid leukemia and 
non-Hodgkin's lymphoma [60].  
Exposure to chemotherapy can up-regulate tumor P-gp expression, which occurs in acquired drug 
resistance [61] and severely limits the success of chemotherapy [54,62]. In small cell lung cancer, 
acquired resistance to multiple drugs is responsible for a chemotherapeutic cure rate below 10% [63]. 
In breast cancer, 55% of the tumors expressed P-gp 55% before and 100% after chemotherapy [64]. 
MDR1 inhibitors have been clinically tested in order to block drug efflux. Specific modulators or 
inhibitors such as GG918 and LY335979 have overcome the toxic adverse effects noted in first 
generation modulators but still have minor effect when co-administrated with chemotherapeutics in 
trials [65,66] in part due to MDR1 polymorphisms [32]. Toxins 2010, 2  
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4. Globotriasosylceramide (Gb3) and MDR1 Expression 
Little is known about the molecular mechanism underlying MDR1  overexpression and how it 
interacts with other genes to impart drug-resistance. Overexpression of glucosylceramide synthase 
(GCS), the first enzyme of GSL synthesis, can result in multidrug resistance. Many cells expressing 
MDR1 show elevated levels of glucosylceramide (GlcCer) [67,68], and inhibitors of GCS kill MDR 
cells [69]. MDR1 can translocate glucosylceramide into the Golgi apparatus for neutral GSL synthesis, 
including Gb3. P-gp has been proposed as a Golgi glucosylceramide flippase that enhances neutral 
GSL synthesis as transfection of MDR1 increases, and inhibition of P-gp decreases neutral GSL 
biosynthesis in cells [70]. GCS up-regulates MDR1  expression and modulates drug resistance   
of cancer. 
Partial MDR1 and Gb3 cell surface co-localization has been observed and inhibition of GSL 
biosynthesis depletes cell surface MDR1. MDR1 may therefore interact with Gb3.  A significant 
fraction of surface MDR1 is not co-localized with Gb3, and could therefore be VT-1-insensitive. 
MDR1 can be expressed in cells lacking Gb3. However, drug-resistant metastatic ovarian tumor cells 
have a particularly high Gb3 content [49] and Gb3 is highly expressed in metastatic colon   
carcinoma [50].  
The water-soluble Gb3 mimic adamantylGb3, but not other GSL analogs, reversed MDR1-MDCK 
cell drug resistance [51]. Verotoxin-mediated Gb3 endocytosis also up-regulated total MDR1 and 
inhibited drug efflux [71]. 
The Gb3 content, which is regulated by the expression of Gb3 synthase, was demonstrated to 
determine the sensitivity of HeLa cells toward VT-1 [72]. We recently demonstrated extensive 
variability in breast cancer cell lines for apoptosis induction by VT-1. Sensitivity was correlated with 
Gb3 expression, and use of the drug PPMP, which down-regulates glucosylceramide production, 
inhibited VT-1-mediated apoptosis [22]. Verotoxin-1 has shown efficacy against meningioma, 
astrocytoma and renal tumor xenografts in mice [73–75]. 
5. Tumor Targeting 
The possibility that VT-1 through the A-subunit could cause protein synthesis inhibition and induce 
apoptosis in normal cells constitutes a concern for the use of the holotoxin as an anticancer agent. The 
non-toxic VT-1 B subunit is stable at extreme pH, resists proteases, crosses tissue barriers, distributes 
in the organism and generally resists extra- and intracellular inactivation [76]. The receptor selectivity 
of the B subunit has therefore been used to couple it to cytotoxic compounds such as the 
topoisomerase I inhibitor SN38 [77] or induce an immune response [78] with preferential effects on 
cancer cells.  
Of primary cultures of gastrointestinal tumors, 80% were found to bind the VT-1 B subunit and 
could be detected on tumor cells after five days. The stable association of VT-1 B subunit with cells 
might be a useful property for diagnostic or therapeutic delivery strategies. This subunit has little 
immunologic properties [79] and is well tolerated in a mouse model [44].  
An apparent treatment possibility to reverse MDR is to inhibit GSL biosynthesis by inhibiting GCS 
or Gb3 synthase enzyme expression and/or activity, or use Gb3 mimics like adamantylGb3 [51].  Toxins 2010, 2  
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The treatment obstacle of acquired-cisplatin resistance in malignant plural mesothelioma (MPM) 
and other cancers makes it necessary to find new strategies to overcome resistance. We showed that 
cisplatin can up-regulate Gb3 expression in MPM and NSCLC cells and thus sensitize the cells to  
VT-1-induced cytotoxicity (Figure 1). The increased proportion of Gb3-expressing cells after cisplatin 
treatment suggests that cisplatin induces Gb3 expression in cancer cells, that cisplatin preferentially 
eradicates cell with low Gb3 expression and that Gb3 expression is linked to acquired   
cisplatin-resistance [15]. We could also correlate increased expression of Gb3 in cisplatin-resistant 
MPM and NSCLC cells to increased expression of MDR1/PgP. PPMP reduced Gb3 expression in 
resistant sub-line cells and particularly of the Gb3-expressing fraction that was induced when the 
mother cell line was made cisplatin-resistant. A strong super-additive effect of combined cisplatin and 
a sub-toxic concentration of VT-1 in cisplatin-resistant malignant pleural mesothelioma cells were 
observed, indicating a new potential and urgently needed clinical treatment approach [15]. 
Figure 1. Flow cytometry analysis of membrane bound Gb3 expression by cultured 
cisplatin-resistant (res) and non-resistant malignant pleural mesothelioma cells (P31) and 
non-small cell lung cancer cells (H1299) not incubated with and cells incubated for 72  h 
with 5  mg  L
–1 cisplatin or 0.1  μg L
–1 VT-1, respectively. The percentage of Gb3-expressing 
cells is noted in the right quadrant in each dot plot. Blank shows unspecific secondary  
antibody binding, whereas control shows cells not incubated with either cisplatin or VT-1. 
Cisplatin resulted in further enhanced Gb3 expression, while VT-1 treatment resulted in a 
complete eradication of the Gb3 expressing cell population [15]. 
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The MAPK pathway is involved in proapoptotic signaling of VT-1 in stressed cell systems and the 
pathway is also involved in cisplatin-induced apoptosis and induced cisplatin resistance [15,80]. 
Targeting the MAPK signaling pathway could, therefore, be an additional way to reduce   
cisplatin-induced tumor cells resistance.  
The partial cell surface co-localization of Gb3/MDR1, the modulation of MDR1 cell surface 
expression by GSL and the possibility to inhibit MDR1 expression by VT-1/VT-1 B-subunit, all 
indicate a functional link between Gb3 and MDR1. Targeting the physiological regulation of MDR1 
could be an efficient way not only to prevent the development of drug resistance during cancer 
chemotherapy but also to reverse inherent and acquired drug resistance of cancers. 
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